Skip to main content

Table 1 Clinical characteristics of the study population

From: Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain

  T2DM (n = 50) Control (n = 32) p value
Age (year) 55 ± 7 54 ± 6 0.483
Male (n, %) 28 (56) 17 (53.1) 0.799
BMI (kg/m2) 24.7 ± 3.7 23.7 ± 2.3 0.165
Diabetes duration (year) 10 (6–13)
HR (bpm) 69 ± 9 66 ± 9 0.128
SBP (mmHg) 128 ± 14 124 ± 10 0.215
DBP (mmHg) 78 ± 10 75 ± 8 0.159
Hypertension (n, %) 19 (38)
Diabetic complication (n, %)
 Retinopathy 14 (28)
 Neuropathy 10 (20)
 Peripheral vascular disease 6 (12)
 Hematocrit (%) 39.3 ± 4.1 41.7 ± 3.7 0.009*
 BUN (mmol/L) 5.3 ± 1.6
 Creatinine (μmol/L) 68.9 ± 14.7
 Total cholesterol (mmol/L) 4.4 ± 1.0
 Triglycerides (mmol/L) 1.62 ± 1.2
 HDL-C (mmol/L) 1.3 ± 0.3
 LDL-C (mmol/L) 2.5 ± 0.7
 FPG (mmol/L) 8.3 ± 3.3
 Hemoglobin A1C (%) 8.9 ± 2.3
Hypoglycemic medication, n (%)
 Insulin 24 (48)
 Metformin 22 (44)
 Sulfonylurea 10 (20)
Other medication, n (%)
 Statin 21 (42)
 Aspirin 16 (32)
 ACEI 20 (40)
 Diuretics 5 (10)
 Calcium channel blockers 5 (10)
 β-blockers 9 (18)
  1. All data are expressed as the means ± SDs, percentages (numbers of participants), or medians (interquartile ranges) as appropriate
  2. DM diabetes mellitus, BMI body mass index, HR heart rate, SBP systolic blood pressure, DBP diastolic blood pressure, BUN blood urea nitrogen, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, FPG fasting plasma glucose, ACEI angiotensin-converting enzyme inhibitor
  3. p < 0.05 between groups